



---

Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 30 April 2021

---

## Lapsing of Unlisted Options

---

**Sydney 30 April 2021:** Australian clinical-stage drug development company **Noxopharm Limited (ASX:NOX)** advises that the following unlisted options have been cancelled on 29 April 2021:

ASX Unquoted Securities	Number of Options	Exercise Price
NOXAT	250,000	the VWAP for the last 14 trading days on the ASX prior to the date of exercise in addition to a further 20% of that amount

Subsequent to the cancellation noted above, unquoted securities on issue are outlined in Appendix A.

**-ENDS-**

*Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR).

To learn more, please visit: [noxopharm.com](http://noxopharm.com)

**Investor, Corporate & Media enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks  
T: +61 2 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

## Appendix A: Unquoted +securities (total number of each class of securities issued but not quoted on ASX)

ASX security code and description	Total number of +securities on issue
Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2018 -Vested (NOXAT)	128,782
Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2019 - <b>Vested</b> (NOXAT)	128,782
Unlisted Option Expiry, 30/11/2021, Exercisable @ \$1.08, vest if employed at 1 December 2020 (NOXAT)	128,779
Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2019 – <b>Vested</b> (NOXAT)	288,680
Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2020 (NOXAT)	288,680
Unlisted Option Expiry, 21/11/2022, Exercisable @ \$0.62, vest if employed at 21 November 2021 (NOXAT)	288,682
Unlisted Options 48 months from the date of issue ( <u>or</u> 23/07/2023), Exercisable @ \$0.560471 (NOXAT)	4,722,222
Unlisted Options Expiry, 16/12/2023, Exercisable @ \$0.35, vest if employed at 16 December 2020 (NOXAT)	930,128
Unlisted Options, Exercisable @ \$0.315, Vesting in 3 tranches subject to performance milestones, expiry 15 December 2022 (NOXAT)	3,000,000
Unlisted Options, Exercisable @ the VWAP for the last 14 trading days on the ASX prior to the date of exercise in addition to a further 20% of that amount, Vesting in 2 tranches, expiry 15 December 2024 (NOXAT)	250,000 <u>(250,000)</u> 0
<b>Total (NOXAT)</b>	10,154,735 <u>(250,000)</u> <b>9,904,735</b>
Unlisted Options Expiry 6 November 2024, Exercisable @ \$0.55 if employed at 6/11/2021 ( <b>NOXAV</b> )	1,050,000
<b>Total (NOXAV)</b>	<b>1,050,000</b>
Replacement Convertible Notes # 1 (balance to be repaid in cash)	2
Replacement Convertible Notes # 2 (balance to be repaid in cash)	2
<b>Total (NOXAU)</b>	<b>4</b>